Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for steroid-resistant/relapse immune thrombocytopenia
NCT05446831Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
baricitinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05446831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446831.